ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT




On July 24, 2021, Quidel Corporation ("Quidel"), Quidel Cardiovascular Inc., a
wholly-owned subsidiary of Quidel ("QCI") and Beckman Coulter, Inc. ("Beckman
Coulter") entered into a Master Agreement (the "Master Agreement") pursuant to
which, among other matters, QCI's business of selling and distributing the BNP
Test for the Beckman Coulter Access Family of Immunoassay Systems (the "BNP
Business") will be transitioned to Beckman Coulter. Pursuant to the Master
Agreement, on a country by country basis, QCI will discontinue offering its
Triage® BNP assay and Beckman Coulter will offer its own branded BNP assay to
the market. Prior to Beckman Coulter introducing its own branded product to the
market, in certain countries, QCI will grant Beckman Coulter exclusive rights to
distribute the Triage® BNP assay in such countries. The parties are targeting
the initial commercial transition, including in the US, to be completed by late
August 2021. Prior to the initial commercial transition to Beckman Coulter, QCI
will continue to operate the Triage® BNP Business.

Under the Master Agreement, as consideration for the transactions contemplated
thereby, during each of calendar years 2022 through and including 2029, Quidel
will receive a minimum payment of $70 million (with amounts of $17.5 million
payable quarterly), and a maximum payment of $75 million, with the additional
$5 million dependent on sales volume of Beckman Coulter assays. Such minimum and
maximum payments will be pro-rated for 2021, based on the period commencing on
the date of the initial commercial transition through December 31, 2021. The
consideration is payable for, among other items, Quidel's continued supply to
Beckman Coulter of the Quidel antibody that Beckman Coulter uses in the
manufacture of the BNP assay, and the settlement of the litigation between
Beckman Coulter and Quidel as discussed below.

Pursuant to the Master Agreement, Quidel and Beckman Coulter concurrently
entered into a settlement agreement to resolve all disputes relating to the
parties' existing BNP Supply Agreement, among other matters, and within five
business days, Beckman Coulter will dismiss with prejudice the complaint against
Quidel that was filed in the Superior Court for the County of San Diego,
California.

In addition, the parties entered into other related agreements under the Master
Agreement, including a Transition Services Agreement, pursuant to which the
parties will provide various transitional services, a Supply Agreement for the
supply by QCI of the Quidel antibody and other components used in the
manufacture of the BNP assay, and a Distribution Agreement, granting Beckman
Coulter the right to sell and distribute the Triage® BNP assay as described
above.

The Master Agreement and the related agreements contains customary representations, warranties and covenants made by each of QCI, Quidel and Beckman, as well as mutual indemnification obligations.

ITEM 7.01 REGULATION FD DISCLOSURE




On July 26, 2021, Quidel issued a press release announcing the settlement of the
above referenced litigation and the transition of the BNP Business to Beckman
Coulter. A copy of the press release is attached as Exhibit 99.1 to this current
report on Form 8-K.

The information in this Item 7.01 of this current report on Form 8-K, including
Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of such section. Such information shall
not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS




(d)  Exhibits

Exhibits

10.1 Master Agreement, dated as of July 24, 2021, by and among Quidel Corporation, Quidel Cardiovascular, Inc., and Beckman Coulter, Inc. +

99.1 Press release, dated July 26, 2021

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

+ The schedules and similar attachments to this exhibit have been omitted

pursuant to Item 601(a)(5) of Regulation S-K. Quidel agrees to furnish

copies of any such schedules or similar attachments to the Securities and

Exchange Commission ("SEC") upon request. In addition, certain provisions of

this exhibit have been redacted because Quidel customarily treats the

redacted information as private or confidential and the omitted information

is not material. Quidel agrees to promptly provide to the SEC on a

supplemental basis an unredacted copy of the exhibit.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses